2
Supplemental digital content
SDC TABLE – Patient status, laboratory data and medication at study entry in HBoV+ and HBoV- groups
(n=46) / HBoV- (n=186) / P
Respiratory symptom score, points (scale 0 - 12) / 6.9 (1.8) / 6.3 (1.7) / 0.021
O2-saturation, % / 96 (3) / 96 (2) / 0.43
Acute otitis media, No. / 20 (%) / 79/185 (43%) / 0.92
Blood eosinophils, x109/L / 0.3 (0.1, 0.5) / 0.2 (0.1, 0.5) / 0.26
Exhaled nitric oxide, ppb / 5.5 (4.4, 9.4) / 5.8 (3.8, 8.1) / 0.44
Any virus, No. / 46 (100%) / 175 (94%) / 0.13
Rhinovirus, No. / 17 (37%) / 77 (41%) / 0.58
Enteroviruses, No. / 5 (11%) / 54 (29%) / 0.011
Respiratory syncytial virus, No. / 9 (20%) / 56 (30%) / 0.15
Adenovirus, No. / 7 (15%) / 10 (5%) / 0.051
Parainfluenza virus types 1-4, No. / 0 (0%) / 20 (11%) / 0.016
Influenza A or B virus, No. / 1 (2%) / 6 (3%) / 0.71
Coronavirus 229E, OC43, NL63 or HKU1, No. / 0 (0%) / 3 (2%) / 1.00
Metapneumovirus, No. / 0 (0%) / 4 (2%) / 0.59
Polyoma virus WU or KI, No. / 0 (0%) / 9 (5%) / 0.21
Mixed viral infection, No. / 34 (74%) / 54 (29%) / <0.0001
Albuterol at ER, mg/kg / 0.31 (0.25) / 0.25 (0.20) / 0.10
Antibiotic treatment, No. / 25 (%) / 87 (47%) / 0.36
Antibiotic treatment started, days after entry / 1 (0, 1) / 0 (0, 0) / 0.73
ICS on entry to the study, No. / 2 (4%) / 21 (11%) / 0.16
ICS started/continued after discharge, No. / 6 (13%) / 43 (23%) / 0.13
ICS started/continued 2 weeks after discharge, No. / 8 (17%) / 66 (35%) / 0.018
Study drug, No. / 25 (54%) / 92 (49%) / 0.55
RSS, respiratory symptom score at study entry; ER, emergency room (before entry to the study).
Values are means (SD) or medians (interquartile range), unless otherwise noted. Analysis using t-test, Mann Whitney U test, Chi square test, or Fischer Exact test (counts < 5) when appropriate.